Table 1 Summary of the study cohort’s clinicopathological information. Note that Patient C* presented without metastasis initially. However, he was found to have bone marrow metastases in bilateral femurs after uneventful completion of his radiotherapy
From: Cerebrospinal fluid cytokines in metastatic group 3 and 4 medulloblastoma
Patient label | Gender | Extent of resection | Histological subtype | Molecular subtype | MYC Amplification (Yes/ No/ N.D.) | Metastasis at initial diagnosis (radiological) | Location of metastasis | CSF cytology positive (Yes/ No) | Clinical status |
|---|---|---|---|---|---|---|---|---|---|
A | Female | GTR | Classic | Group 3 | No | No | N.A. | No | Disease remission at 15 months |
B | Female | GTR | Classic | Group 3 | No | No | N.A. | No | Disease remission at 11 months |
C* | Male | NTR | Classic | Group 3 | Yes | No* | N.A.* | No | Passed away from disease progression |
D | Female | NTR | Large cell anaplastic | Group 3 | Yes | Yes | Intracranial, spine | No | Passed away from disease progression |
E | Female | GTR | Classic | Group 3 | No | Yes | Intracranial, spine | No | Alive; receiving RT |
F | Male | NTR | Classic | Group 4 | N.D. | No | N.A. | No | Disease remission at 20 months |
G | Male | GTR | Classic | Group 4 | N.D. | No | N.A. | No | Disease remission at 22 months |
H | Male | NTR | Classic | Group 4 | N.D. | Yes | Intracranial, spine | No | Disease remission at 18 months |
I | Male | GTR | Classic | Group 4 | N.D. | Yes | Intracranial, spine | No | Passed away at 13 months from relapse |
J | Male | NTR | Classic | Group 4 | N.D. | Yes | Pituitary gland | No | Disease regression; receiving chemotherapy |